1859, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
1859, Inc. - overview
Established
2019
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in San Diego, CA, US, and founded in 2019 by Devon Cayera and Andrew MacConnell, 1859, Inc. is a biotechnology company focusing on the discovery and development of next-generation therapeutics. In February 2022, 1859, Inc. raised USD 40 million in series A financing by investors Northpond Ventures, OMX Ventures, FusionX Ventures and Vertical Venture Partners.
The company's platform helps in creating new medicine, enabling scientists to parallelize the discovery of new medicines by combining datasets generated from pico-scale screening of novel chemical libraries with artificial intelligence predictions. 1859, Inc. plans to use the funding to support the development of new capabilities, and the scaling and advancement of preclinical discovery programs building upon a base of 16 pharmaceutical, biotech and academic partners.
Current Investors
Vertical Venture Partners, FusionX Ventures, Northpond Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.eighteenfiftynine.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.